Aesica Pharmaceuticals Receives Majority Investment from Silverfleet Capital
Aesica Pharmaceuticals, a Cramlington, UK-based company that develops and manufactures primary (API) and secondary stage (finished product dosage forms) pharmaceuticals, has received a majority investment from Silverfleet Capital.
Aesica executives have reinvested for a large minority stake in the company. Debt financing will be provided by Lloyds Bank Corporate Markets Acquisition Finance, HSBC and Yorkshire Bank.
Silverfleet Capital, which will replace LDC‘s majority shareholding in the business subject to completion, will help Aesica continue to grow and expand into new markets.
Led by CEO Dr Robert Hardy, the company currently operates six manufacturing sites across Europe and sales representation across the US, Europe and Asia and intends to extend its capabilities and global manufacturing facilities.
In conjunction with the investment, which is subject to obtaining clearance from the German authorities, Silverfleet Capital’s David Mackenzie and Adrian Yurkwich will join the company’s board as a non-executive director.